Communiqués Telix Pharmaceuticals Limited

Actions

TLX

AU000000TLX2

Marché Fermé - Australian S.E. Autres places de cotation 08:10:06 16/07/2024			Varia. 5j.	Varia. 1 janv.
19,93 ^AUD	-0,05 %		+10,72 %	+97,72 %

11/07	Les actions australiennes atteignent leur plus haut niveau depuis plus de trois mois suite aux commentaires du président de la Fed	MT
06/06	Telix Pharmaceuticals lance une introduction en bourse de 200 millions de dollars aux Etats-Unis	MT

Communiqués

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

Telix Welcomes CMS Proposal to Improve Payment for Specialised Diagnostic Radiopharmaceuticals	11/07	AQ
Telix Announces Launch of Proposed Initial Public Offering in the United States	05/06	AQ
Telix Completes TLX250-CDx (Zircaix™) BLA Submission for Kidney Cancer Imaging	03/06	AQ
Telix Announces Positive rPFS Data from ProstACT SELECT Trial of TLX591 rADC Therapy Candidate in Prostate Cancer	31/05	AQ
Telix Submits NDA for New Prostate Cancer Imaging Agent	28/05	AQ
Telix Completes Proof-of-Concept Study of TLX592 Targeted Alpha Therapy in Prostate Cancer	21/05	AQ
Telix Files Registration Statement for Proposed Initial Public Offering in the United States	17/05	AQ
Telix to Showcase Extensive Urologic Pipeline at AUA Annual Meeting including Phase III ProstACT GLOBAL Study of TLX591	01/05	AQ
Telix - Notice of Annual General Meeting 2024	22/04	AQ
Q1 2024 Revenue and Business Update	17/04	AQ
TLX101-CDx (Pixclara™) Granted FDA Fast Track Designation	16/04	AQ
Telix Pharmaceuticals Limited completes the acquisition of ARTMS, Inc.	11/04	BU
Telix Pharmaceuticals - World First Use of Lightpoint's SENSEI Drop-In Gamma Probe in Bladder Cancer Surgery Performed in Spain	27/03	AQ
World First Use of Lightpoint's SENSEI® Drop-In Gamma Probe in Bladder Cancer Surgery Performed in Spain	26/03	AQ
QDOSE Platform Partnership for Personalized Dosimetry in Radiopharmaceutical Therapy	19/03	AQ
QDOSE® Platform Partnership for Personalized Dosimetry in Radiopharmaceutical Therapy	18/03	AQ
Appointment of Dr Darren Patti to Group Chief Operating Officer	11/03	AQ
Telix to Acquire ARTMS, Inc. and its Advanced Isotope Production Platform	04/03	AQ
Telix Expands U.S. Development and Manufacturing Infrastructure with Acquisition of IsoTherapeutics	26/02	AQ
Telix 2023 Full Year Results: Inaugural Profit Achieved, Strong Revenue Growth Underpins Investment in Late-stage Pipeline	22/02	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Telix Pharmaceuticals Limited

Actions

TLX

AU000000TLX2

Communiqués

Filtres